Given the significant future potential of Farxiga, the Company continues to prioritise commercial support over Onglyza
A 2018 review noted that cardiovascular outcome trials for alogliptin (Nesina), saxagliptin (Onglyza
), and sitagliptin (Januvia) showed noninferiority but failed to demonstrate any superiority, compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk (Circ Res.
purchase Bristol-Myers Squibb's diabetes drugs, including Onglyza
These studies reinforce the use of dapagliflozin as a treatment option to help improve glycemic control when used with the DPP-4 inhibitor Onglyza
versus older treatment options in patients with T2D.
Persons with diabetes, who are controlled on diet, metformin or DDP4 Inhibitors (januvia , Galvus, onglyza
) can undertake fasting like any other person as the risk of hypoglycemia is least with these drugs.
* Sitagliptin (Januvia), saxagliptin (Onglyza
), linagliptin (Tradjenta) and alogliptin (Nesina) are inhibitors of DDP-4, an enzyme responsible for breakdown of incretin hormones.
There are four drugs in this subclass: alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin (Onglyza
), and sitagliptin (Januvia).
TYPES AND NAMES OF DIABETES MEDICATIONS* CLASS BRAND NAMES Biguanides Glucophage, Fortamet GLP-1 receptor agonists Trulicity, Tanzeum, Bydureon, Victoza DPP-IV inhibitors Januvia, Onglyza
, Nesina SGLT-2 inhibitors Invokana, Farxiga, Jardiance Sulfonylureas Amaryl, Glucotrol, DiaBeta, Glynase Insulin Tresiba, Toujeo, Afrezza, Levemir, Lantus Combination drugs Janumet, Jentadueto, Kombiglyze, Tradjenta, Kazano, Oseni * This chart provides examples of some, but not all, medications used to treat diabetes.
Meanwhile, British-Swedish rival AstraZeneca has seen its diabetes medicine Onglyza
and lung cancer medicine Iressa (gefitnib) added to the list.
Sitagliptin (Januvia), saxagiptin (Onglyza
) and linaglipin (Tradgenta) were approved by the FDA.
Experts also discuss the positive cardiovascular safety data published for Victoza in the LEADER trial, and shed light on the recent US-FDA issued warnings about heart failure risk to the labels of T2DM medicines containing saxagliptin (Onglyza
) and alogliptin (Nesina).
On August 18, 2015, the Controller of Patents Office in India rejected the Lee Pharma's compulsory licence application for AstraZeneca's Saxagliptin, sold under the brand name Onglyza
and Kombiglyze, and prescribed for Type-II Diabetes Mellitus on all the three grounds of Section 84(1): (a) that the substitutes to the drug are readily available in the market; (b) the claim that requirements of public with respect to the patented invention are not being satisfied has not been proven; and (c) the applicant has failed to prima facie demonstrate that the patented invention is not worked in the territory of India.